HCA Healthcare, Inc. (NYSE:HCA) will release earnings results for the third quarter, before the opening bell on Friday, Oct. 24.Analysts expect the Nashville, Tennessee-based company to report quarterly earnings at $5.73 per share, up from $4.90 per share in the year-ago period. The consensus estimate for HCA Healthcare's quarterly revenue is $18.56 billion, compared to $17.49 billion a year earlier, according to data from Benzinga Pro.On July 25, HCA Healthcare posted better-than-expected earnings for the ...

Lake Success, New York-based Broadridge Financial Solutions, Inc. (BR) provides investor communications and technology-driven solutions for the financial services industry. With a market cap of $26.7 billion, Broadridge operates through Investor Communication Solutions (ICS), Global Technology and Operations (GTO), and other segments. The financial IT services provider is gearing up to announce its first-quarter results before the market opens on Tuesday, Nov. 4. Ahead of the event, analysts expect BR to ...

Core Viewpoint - W. R. Berkley Corporation is expected to report improved earnings and revenue for the third quarter compared to the previous year, indicating positive financial performance [1]. Earnings Expectations - The company is projected to report earnings of $1.10 per share for the third quarter, an increase from $0.93 per share in the same period last year [1]. - The consensus estimate for quarterly revenue is $3.15 billion, up from $2.93 billion a year earlier [1]. Recent Performance - In the second quarter, W. R. Berkley posted mixed results, with shares closing at $74.05, reflecting a 0.5% gain [2]. Analyst Ratings - UBS analyst Brian Meredith maintained a Buy rating and increased the price target from $80 to $87 [4]. - Wells Fargo analyst Elyse Greenspan maintained an Equal-Weight rating and raised the price target from $68 to $69 [4]. - Barclays analyst Alex Scott maintained an Underweight rating and boosted the price target from $62 to $66 [4]. - Keefe, Bruyette & Woods analyst Meyer Shields maintained a Market Perform rating and raised the price target from $65 to $75 [4]. - B of A Securities analyst Joshua Shanker downgraded the stock from Buy to Neutral while raising the price target from $73 to $74 [4].

The Clorox Company (CLX) is a California-based consumer products firm best known for its cleaning, household, and personal care brands. With a market cap of $14.6 billion, it operates in over 100 countries with about 8,000 employees. The company is expected to release its Q1 results after the market closes on Monday, Nov. 3. Ahead of the event, analysts expect CLX to report an EPS of $0.78, down 58.1% from $1.86 reported in the year-ago quarter. The company has exceeded Street’s bottom-line estimates in t ...

Core Insights - The Bank of New York Mellon Corporation (NYSE:BK) is set to release its third-quarter earnings results on October 16, with analysts expecting earnings of $1.77 per share, an increase from $1.52 per share in the same period last year [1] - The projected quarterly revenue for BNY Mellon is $4.98 billion, up from $4.65 billion a year earlier [1] Financial Activities - On September 3, BNY Mellon announced a public offering of $500 million in depositary shares representing interests in preferred stock [2] - The stock price of Bank of New York Mellon increased by 0.8%, closing at $107.11 on a recent Tuesday [2] Analyst Ratings - Goldman Sachs analyst Alexander Blostein maintained a Buy rating and raised the price target from $106 to $120 [4] - BMO Capital analyst Brennan Hawken initiated coverage with an Outperform rating and a price target of $125 [4] - Truist Securities analyst David Smith maintained a Hold rating and increased the price target from $109 to $118 [4] - Evercore ISI Group analyst Glenn Schorr maintained an In-Line rating and raised the price target from $91 to $110 [4] - Citigroup analyst Keith Horowitz maintained a Neutral rating and increased the price target from $92 to $105 [4]

Core Insights - Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines for serious diseases, with a market cap of $59.1 billion, and is set to announce its fiscal Q3 earnings for 2025 on October 28 [1] Financial Performance - Analysts expect Regeneron to report a profit of $7.80 per share for Q3 2025, a decrease of 33.5% from $11.73 per share in the same quarter last year [2] - For fiscal 2025, the expected profit is $32.36 per share, down 16.2% from $38.62 per share in fiscal 2024, with a further decline of 2.4% anticipated for fiscal 2026 [3] Stock Performance - Regeneron's stock has declined 44.9% over the past 52 weeks, underperforming compared to the S&P 500 Index's 12.3% return and the Health Care Select Sector SPDR Fund's 8.6% drop [4] - Following a better-than-expected Q2 earnings release, Regeneron's shares surged 2.5%, with overall revenue improving 3.6% year-over-year to $3.7 billion, exceeding analyst expectations by 10.2% [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for Regeneron, with 18 out of 27 analysts recommending "Strong Buy," and a mean price target of $729.85, indicating a potential upside of 29.5% from current levels [6]

Core Insights - Comcast Corporation (CMCSA) has a market capitalization of $108.8 billion and operates as a global media and technology conglomerate, evolving from a regional cable provider to a diversified entity with significant operations in broadband, wireless, video, and voice services [1] Financial Performance Expectations - Analysts anticipate that Comcast will report a profit of $1.10 per share for the third quarter, reflecting a 1.8% decrease from the $1.12 per share reported in the same quarter last year [2] - For the current year, earnings are expected to decline by 1.2% from $4.33 per share in 2024 to $4.28 per share, but a growth of 4.4% is projected for fiscal 2026, reaching $4.47 per share [3] Stock Performance - Over the past 52 weeks, CMCSA stock has decreased by 28.7%, significantly underperforming the S&P 500 Index, which gained 14.4%, and the Communication Services Select Sector SPDR ETF Fund, which surged by 25.9% [4] - On October 10, CMCSA shares fell by 2.1% after Bernstein analyst Laurent Yoon maintained a "Hold" rating with a price target of $36, while the overall consensus rating is "Moderate Buy" with a mean price target of $39.91, indicating a 35.7% premium to current price levels [5]

Core Insights - Otis Worldwide Corporation, based in Farmington, Connecticut, specializes in vertical transportation systems, including elevators, escalators, and moving walkways, with a market capitalization of $35.8 billion [1] Financial Performance - Analysts anticipate Otis to report a fiscal Q3 profit of $1 per share, reflecting a 4.2% increase from $0.96 per share in the same quarter last year [2] - For the current fiscal year ending in December, the expected profit is $4.03 per share, a 5.2% rise from $3.83 per share in fiscal 2024, with further growth projected to $4.32 per share in fiscal 2026, representing a 7.2% year-over-year increase [3] Stock Performance - Over the past 52 weeks, Otis shares have decreased by 9.8%, underperforming the S&P 500 Index, which rose by 17.4%, and the Industrial Select Sector SPDR Fund, which increased by 14.8% [4] - Following the mixed Q2 results, Otis shares fell by 12.4%, with overall revenue declining slightly year-over-year to $3.6 billion, which was 2.2% below analyst expectations [5] Analyst Ratings - The overall consensus among Wall Street analysts is a "Hold" rating for Otis, with four recommending "Strong Buy," one suggesting "Moderate Buy," six advising "Hold," and two indicating "Strong Sell" [6] - The mean price target for Otis is $99.91, suggesting a potential upside of 9.5% from current levels [6]

Core Insights - Equifax Inc. (EFX) is a leading global data, analytics, and technology company with a market cap of $31.5 billion, set to announce its fiscal third-quarter earnings for 2025 on October 15 [1] Earnings Expectations - Analysts anticipate EFX to report a profit of $1.94 per share on a diluted basis, reflecting a 4.9% increase from $1.85 per share in the same quarter last year [2] - For the full year, EPS is expected to be $7.56, up 3.7% from $7.29 in fiscal 2024, with a projected rise to $9.13 in fiscal 2026, representing a 20.8% year-over-year increase [3] Stock Performance - EFX stock has underperformed the S&P 500 Index, which gained 15.6% over the past 52 weeks, with EFX shares down 12.5% during the same period [4] - The stock also lagged behind the Industrial Select Sector SPDR Fund's 13.3% gains in the same timeframe [4] Market Challenges - The underperformance of Equifax is attributed to macroeconomic challenges, including a weak mortgage market due to high interest rates and home prices, reduced hiring, and regulatory issues [5] - Despite maintaining full-year revenue guidance, the company's cautious outlook due to economic uncertainties may have negatively impacted investor sentiment [5] Recent Financial Results - On July 22, EFX shares fell over 8% after reporting Q2 results, with adjusted EPS of $2 exceeding Wall Street expectations of $1.92, and revenue of $1.54 billion surpassing forecasts of $1.51 billion [6] - EFX expects full-year adjusted EPS in the range of $7.33 to $7.63, with revenue projected between $5.97 billion and $6.04 billion [6] Analyst Ratings - Analysts maintain a reasonably bullish consensus on EFX stock, with a "Moderate Buy" rating overall; 11 analysts recommend a "Strong Buy," three suggest a "Moderate Buy," and 10 give a "Hold" [7] - The average analyst price target for EFX is $279.81, indicating a potential upside of 10% from current levels [7]

Group 1 - Flux Power Holdings, Inc. is expected to report a quarterly loss of 8 cents per share for Q4, an improvement from a loss of 16 cents per share a year ago [1] - Projected quarterly revenue for Flux Power is $16.47 million, up from $13.23 million in the same quarter last year [1] - On August 21, Flux Power secured an additional order worth over $1.2 million from a major North American airline, leading to a 6.5% increase in share price to close at $1.80 [2] Group 2 - HC Wainright & Co. analyst Amit Dayal maintained a Buy rating but reduced the price target from $15 to $8 [7] - Maxim Group analyst Matthew Galinko also maintained a Buy rating, lowering the price target from $6 to $4 [7] - Craig-Hallum analyst Eric Stine kept a Buy rating while cutting the price target from $10 to $7 [7]